Other

Solae, LLC

Protein Technologies International, Inc.

Mobile-plan-it, LLC

Archer Daniels Midland Company

Jens Horstmann

Susan M Potter

Doyle H Waggle

Jens U Horstmann

Saeed Zarea

Matti Katajamaki

Miroslav Charles Wiesner

Edna C Henley

E C Henley

Richard B Taylor

An organizer uses software to define a conference or meeting to take place at a physical meeting location, and to include a list of attendees. The attendees can receive the meeting information, including the location and attendee list, via client-side software on the wireless telephone. Also via their wireless telephones, the attendees can link to and display pages associated with other attendees, send and receive messages to and from one another, arrange further on-site or offsite meetings, and share various types of personal and business information.

Systems and methods for communicating among meeting attendees via wireless telephones

An organizer uses software to define a conference or meeting to take place at a physical meeting location, and to include a list of attendees. The attendees can receive the meeting information, including the location and attendee list, via handheld wireless devices. Also via their handheld wireless devices, the attendees can link to and display pages associated with other attendees, send and receive messages to and from one another, arrange further on-site or offsite meetings, and share various types of personal and business information.

Wireless telephones and methods for sharing information among and between individuals and groups

A conference organizer uses conference software to define a conference and to store conference information on the organizer's computer system. The stored conference information includes a list of attendees, and a personal proxy mailbox for each attendee. Each attendee has a wireless device, such as a personal digital assistant (PDA). The organizer's computer system includes a wireless communication station that can communicate in wireless fashion with the wireless devices of the attendees at the conference. During the conference, an attendee uses his/her wireless device to access the conference information, select another attendee or a group of attendee from the list of attendees, and send the selected attendee or attendees a message. The message can be conveyed to and stored in the personal proxy mailbox or mailboxes of the selected attendee or attendees. The use of personal proxy mailboxes allows attendees to send messages to one another and to receive messages from one another without divulging their primary email addresses.

Methods and systems for organizing meetings

A conference organizer uses conference software to define a conference and to store conference information on the organizer's computer system. The stored conference information includes a list of attendees, and a personal proxy mailbox for each attendee. Each attendee has a wireless device, such as a personal digital assistant (PDA). The organizer's computer system includes a wireless communication station that can communicate in wireless fashion with the wireless devices of the attendees at the conference. During the conference, an attendee uses his/her wireless device to access the conference information, select another attendee from the list of attendees, and send the selected attendee a message such that the message is stored in the personal proxy mailbox of the selected attendee. The use of personal proxy mailboxes allows attendees to send messages to one another and to receive messages from one another without divulging their primary email addresses.

Interactive wireless device communication system for meetings and conferences

The present invention is a composition comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. The present invention is also a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone.

Method of reducing low density liproprotein cholesterol concentration

A composition is provided comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which the plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. Also provided is a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. A preferred composition contains an isoflavone material free of soy bean protein and at least 0.49% by weight of plant sterol. The isoflavone can be genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides and glycoside conjugates. The plant sterol can be B-sitosterol, campesterol, stigmasterol, sitostanol, or campestanol.

Composition containing isoflavone material and plant sterol for reducing LDL-cholesterol

A composition is provided comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which the plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. Also provided is a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. A preferred composition contains soy hypocotyl material and at least 0.49% by weight plant sterol. The plant sterol can be B-sitosterol, campesterol, stigmasterol, sitostanol, or campestanol.

Composition containing soy hypocotyl material and plant sterol for reducing LDL-cholesterol

A composition is provided comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which the plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. Also provided is a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. A preferred method involves co-administering to a human a plant sterol and a soy protein material containing at least 0.49% by weight soy protein and containing the isoflavone glycoside, glycitin. The plant sterol is at least 0.49% by combined weight of the co-administered plant sterol and soy protein material. The plant sterol can be B-sitosterol, campesterol, stigmasterol, sitostanol, or campestanol. Also an isoflavone can be administered in combination with the plant sterol and soy protein material. This isoflavone can be genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides and glycoside conjugates.

Administering a composition containing plant sterol, soy protein and isoflavone for reducing LDL-cholesterol

A composition is provided comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which the plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. Also provided is also a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. A preferred method involves co-administering to a human a plant sterol and a soy protein material containing at least 49% by weight soy protein and containing the isoflavone glycoside, glycitin. The plant sterol is at least 0.49% by combined weight of the co-administered plant sterol and soy protein material. The plant sterol can be B-sitosterol, campesterol, stigmasterol, sitostanol, or campestanol. Also an isoflavone can be administered in combination with the plant sterol and soy protein material. This isoflavone can be genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides and glycoside conjugates.

Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol

The present invention relates to a hormone replacement therapy, and a composition useful therein, for women having reduced levels of endogenous estrogen. A mammalian estrogen and an isoflavone which is incapable of being metabolized to equol are co-administered to a woman having a reduced level of endogenous estrogen. The hormone replacement therapy is effective to inhibit or prevent diseases or conditions resulting from, or exacerbated by, a reduction in endogenous estrogen including: coronary heart disease, cardiovascular disease, osteoporosis, loss of cognitive function, urinary incontinence, weight gain, fat mass gain, and vasomotor symptoms. A composition for use in the hormone replacement therapy of the present invention contains a mammalian estrogen and at least one isoflavone, where the isoflavone is incapable of being metabolized to equol by a human, and where the composition contains less than 10% by weight of isoflavones and phytoestrogens capable of being metabolized to equol by a human.

Hormone replacement therapy

A method of altering the concentration of cholesterol constituents in human blood is provided. A daidzein material is administered to a human to increase the concentration of HDL-cholesterol and to decrease the level of LDL-cholesterol in the blood. The daidzein material may be administered in a pharmaceutical composition, or in a dietary supplement, including soy protein based dietary supplements. Utilization of daidzein to increase the concentration of HDL cholesterol and to decrease the concentration of LDL-cholesterol in the blood reduces the risk of atherosclerosis and vascular disease by providing more health beneficial HDL-cholesterol and reducing the level of atherosclerosis-inducing LDL-cholesterol.

Growing community of inventors

St. Louis, MO, United States of America

Susan M Potter